15-May-2026
Repligen Shareholders Approve Directors, Auditor and Pay Plan
TipRanks (Fri, 15-May 8:28 AM ET)
TipRanks (Thu, 14-May 6:20 PM ET)
Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference
Globe Newswire (Thu, 7-May 7:30 AM ET)
Repligen Posts Strong Start to 2026 With Double-Digit Revenue Growth and Margin Expansion
Market Chameleon (Tue, 5-May 4:56 AM ET)
Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Globe Newswire (Tue, 5-May 7:00 AM ET)
Repligen to Report First Quarter 2026 Financial Results
Globe Newswire (Wed, 22-Apr 7:30 AM ET)
Globe Newswire (Fri, 17-Apr 7:30 AM ET)
Repligen Corporation to Present at Upcoming March Conferences
Globe Newswire (Thu, 5-Mar 7:30 AM ET)
Globe Newswire (Tue, 24-Feb 7:30 AM ET)
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Repligen trades on the NASDAQ stock market under the symbol RGEN.
As of May 15, 2026, RGEN stock price declined to $102.87 with 2,156,298 million shares trading.
RGEN has a beta of 1.10, meaning it tends to be more sensitive to market movements. RGEN has a correlation of 0.09 to the broad based SPY ETF.
RGEN has a market cap of $5.80 billion. This is considered a Mid Cap stock.
Last quarter Repligen reported $194 million in Revenue and $.48 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.10.
In the last 3 years, RGEN traded as high as $211.13 and as low as $100.99.
The top ETF exchange traded funds that RGEN belongs to (by Net Assets): VTI, IJH, VB, VBK, VXF.
RGEN has underperformed the market in the last year with a price return of -16.5% while the SPY ETF gained +26.4%. RGEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.6% and -12.2%, respectively, while the SPY returned +8.7% and +2.6%, respectively.
RGEN support price is $99.23 and resistance is $107.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RGEN shares will trade within this expected range on the day.